CJC-1295

What is CJC-1295?

CJC-1295 is a thoroughly researched growth hormone-releasing hormone (GHRH) analogue developed by ConjuChem Biotechnologies to extend natural growth hormone production. This synthetic peptide has undergone rigorous Phase I and II clinical trials, making it one of the most scientifically validated peptides for growth hormone optimisation.

The peptide exists in two distinct variants with dramatically different properties. CJC-1295 DAC (Drug Affinity Complex) features albumin-binding modifications extending its half-life to 6-8 days, whilst CJC-1295 No DAC (Modified GRF 1-29) requires daily administration due to its 30-minute half-life.

CJC-1295 Benefits and Clinical Results

Clinical studies demonstrate impressive outcomes in controlled trials. Research indicates healthy adults experienced substantial growth hormone increases lasting up to six days following administration. Studies suggest patients with growth hormone deficiency showed significant IGF-1 normalisation improvements.

Body composition data from 90-day controlled trials indicated participants experienced measurable fat loss and lean mass gains. These results position CJC-1295 as a compelling option for those seeking growth hormone optimisation through evidence-based interventions.

The peptide's mechanism works synergistically with your body's natural rhythms, amplifying existing growth hormone pulses rather than disrupting circadian patterns. This approach differentiates it from synthetic growth hormone replacement, which can suppress natural production.

CJC-1295 Dosage Protocols

Clinical dosing varies significantly between variants. CJC-1295 DAC studies utilised 30mcg/kg bodyweight administered twice weekly, typically resulting in 2mg doses for average adults. The extended half-life allows for convenient dosing schedules.

CJC-1295 No DAC requires more frequent administration, with research suggesting 100mcg doses taken 1-3 times daily before meals or bedtime. Many researchers prefer combining it with Ipamorelin at 100-200mcg doses for synergistic effects.

Dosing timing proves crucial for optimal results. Studies indicate administering CJC-1295 No DAC during natural growth hormone peaks (evening hours) maximises efficacy. Our reconstitution calculator helps determine precise dosing volumes.

CJC-1295 Side Effects and Safety Profile

Clinical trials report generally mild side effects. Common observations include injection site reactions, temporary flushing, and occasional headaches. Some participants experienced increased hunger, likely related to growth hormone elevation.

More concerning potential effects include water retention and joint discomfort, particularly with higher doses or extended use. Studies suggest these effects typically resolve with dose adjustments or temporary discontinuation.

Long-term safety data remains limited, though clinical trials extending 90 days showed no serious adverse events. Researchers emphasise the importance of gradual dose escalation and regular monitoring when using any growth hormone-releasing peptide.

CJC-1295 and Ipamorelin Combinations

Many researchers combine CJC-1295 with Ipamorelin for complementary mechanisms of action. Whilst CJC-1295 stimulates growth hormone release, Ipamorelin amplifies natural pulses through different receptor pathways.

This combination approach allows for lower individual doses whilst potentially achieving superior results. Clinical observations suggest the pairing may reduce side effects associated with higher single-peptide dosing.

Our stack builder tool helps researchers design appropriate combination protocols. Many also incorporate BPC-157 or TB-500 for comprehensive recovery and regeneration support.

UK Legal Status and Availability

CJC-1295 exists in a regulatory grey area within the UK. The peptide isn't scheduled under the Misuse of Drugs Act, yet it's not approved for human consumption. This creates a research-only market where peptides are sold explicitly for laboratory investigation.

Quality varies significantly between suppliers, making source verification crucial. Our supplier directory provides vetted options with third-party testing certificates. Understanding UK peptide legality helps researchers navigate the regulatory landscape appropriately.

Proper peptide storage becomes essential given the investment involved. Both CJC-1295 variants require refrigeration and careful handling to maintain potency throughout research periods.

CJC-1295 functions as a highly selective agonist of the growth hormone-releasing hormone receptor (GHRHR), located on specialised cells called somatotrophs in your anterior pituitary gland. This mechanism operates as a targeted approach that enhances your body's natural growth hormone production systems.

When CJC-1295 binds to these receptors, it activates the cAMP/protein kinase A signalling cascade — essentially initiating growth hormone synthesis and release. This differs from direct growth hormone injection by working through your body's existing regulatory pathways rather than bypassing them entirely.

The peptide's molecular design addresses key stability issues. Native GHRH is rapidly destroyed by the enzyme DPP-4 within minutes of release. CJC-1295's creators solved this by substituting the second amino acid (Ala2) with D-Ala, creating a structure that DPP-4 cannot recognise or cleave. They also replaced Gln16 with Ala to prevent deamidation, another form of molecular breakdown.

In the DAC version, an additional lysine residue allows the peptide to bind reversibly to albumin in your bloodstream. This creates a slow-release reservoir effect, maintaining steady peptide levels for days rather than minutes. The No DAC version lacks this modification, producing more natural, pulsatile growth hormone releases that mirror your body's circadian rhythm.

Once growth hormone enters circulation, it travels to the liver and other tissues, stimulating IGF-1 production. IGF-1 mediates many of the downstream effects — driving protein synthesis, fat oxidation, and cellular repair. This two-step process (CJC-1295 → GH → IGF-1) explains why effects build gradually over weeks rather than appearing immediately.

Unlike Ipamorelin or MK-677, which work through the ghrelin pathway, CJC-1295's GHRHR selectivity provides more targeted outcomes. This selectivity also distinguishes it from Hexarelin and other growth hormone secretagogues that may affect multiple receptor systems. For detailed mechanistic information, consult our peptide mechanisms guide.